Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

  • In development
  • GID-TA10899
  • Expected publication date: TBC
Due to changes in the regulatory review timeline, the timelines for this appraisal are now TBC.